UA85569C2 - Замещенные конденсированные гетероциклические с-гликозиды - Google Patents

Замещенные конденсированные гетероциклические с-гликозиды

Info

Publication number
UA85569C2
UA85569C2 UAA200605347A UAA200605347A UA85569C2 UA 85569 C2 UA85569 C2 UA 85569C2 UA A200605347 A UAA200605347 A UA A200605347A UA A200605347 A UAA200605347 A UA A200605347A UA 85569 C2 UA85569 C2 UA 85569C2
Authority
UA
Ukraine
Prior art keywords
glycosides
fused heterocyclic
substituted fused
substituted
prophylaxis
Prior art date
Application number
UAA200605347A
Other languages
English (en)
Ukrainian (uk)
Inventor
Филипп Рибчински
Мод Урбански
Сяоян Жанг
Original Assignee
Янссен Фармацевтика Н.В.
Танабе Сейяку Ко., Лтд
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Янссен Фармацевтика Н.В., Танабе Сейяку Ко., Лтд filed Critical Янссен Фармацевтика Н.В.
Publication of UA85569C2 publication Critical patent/UA85569C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
    • C07H5/04—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to nitrogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

Данное изобретение относится к замещенным конденсированным гетероцикличным С-гликозидам, композициям, содержащим их, и способам их использования, например, для лечения или профилактики диабета и синдрома X.
UAA200605347A 2003-08-01 2004-07-30 Замещенные конденсированные гетероциклические с-гликозиды UA85569C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US49152303P 2003-08-01 2003-08-01

Publications (1)

Publication Number Publication Date
UA85569C2 true UA85569C2 (ru) 2009-02-10

Family

ID=34115512

Family Applications (5)

Application Number Title Priority Date Filing Date
UAA200605348A UA86042C2 (en) 2003-08-01 2004-07-29 Substituted indazole-o-glucosides
UAA200605346A UA87991C2 (en) 2003-08-01 2004-07-30 Substituted indole-o-glucosides
UAA200602256A UA83377C2 (ru) 2003-08-01 2004-07-30 N-гликозид, способ его получения, фармацевтическая композиция и способ лечения
UAA200605347A UA85569C2 (ru) 2003-08-01 2004-07-30 Замещенные конденсированные гетероциклические с-гликозиды
UAA200605349A UA86599C2 (en) 2003-08-01 2004-07-30 Substituted benzimidazole-, benztriazole- and benzimidazolone-о-glucosides

Family Applications Before (3)

Application Number Title Priority Date Filing Date
UAA200605348A UA86042C2 (en) 2003-08-01 2004-07-29 Substituted indazole-o-glucosides
UAA200605346A UA87991C2 (en) 2003-08-01 2004-07-30 Substituted indole-o-glucosides
UAA200602256A UA83377C2 (ru) 2003-08-01 2004-07-30 N-гликозид, способ его получения, фармацевтическая композиция и способ лечения

Family Applications After (1)

Application Number Title Priority Date Filing Date
UAA200605349A UA86599C2 (en) 2003-08-01 2004-07-30 Substituted benzimidazole-, benztriazole- and benzimidazolone-о-glucosides

Country Status (18)

Country Link
US (1) US7521430B2 (ru)
EP (1) EP1654269B1 (ru)
JP (1) JP4717811B2 (ru)
KR (1) KR101101500B1 (ru)
CN (2) CN1829728A (ru)
AU (1) AU2004260760B2 (ru)
BR (1) BRPI0413233A (ru)
CA (1) CA2534022C (ru)
EA (1) EA011025B1 (ru)
ES (1) ES2527053T3 (ru)
IL (1) IL173051A (ru)
MX (1) MXPA06001273A (ru)
NO (1) NO333679B1 (ru)
NZ (1) NZ545305A (ru)
TW (1) TWI377209B (ru)
UA (5) UA86042C2 (ru)
WO (1) WO2005012321A1 (ru)
ZA (2) ZA200601686B (ru)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8785403B2 (en) 2003-08-01 2014-07-22 Mitsubishi Tanabe Pharma Corporation Glucopyranoside compound
WO2005012326A1 (en) * 2003-08-01 2005-02-10 Tanabe Seiyaku Co., Ltd. Novel compounds having inhibitory activity against sodium-dependant transporter
TW200637869A (en) 2005-01-28 2006-11-01 Chugai Pharmaceutical Co Ltd The spiroketal derivatives and the use as therapeutical agent for diabetes of the same
TWI365186B (en) 2005-01-31 2012-06-01 Mitsubishi Tanabe Pharma Corp Indole derivatives
AR053329A1 (es) * 2005-01-31 2007-05-02 Tanabe Seiyaku Co Derivados de indol utiles como inhibidores de los transportadores de glucosa dependientes del sodio (sglt)
JP5073948B2 (ja) * 2005-01-31 2012-11-14 田辺三菱製薬株式会社 医薬組成物
TWI418556B (zh) * 2006-07-27 2013-12-11 Mitsubishi Tanabe Pharma Corp 吲哚衍生物
TWI499414B (zh) * 2006-09-29 2015-09-11 Lexicon Pharmaceuticals Inc 鈉與葡萄糖第２型共同運輸體（ｃｏ-ｔｒａｎｓｐｏｒｔｅｒ ２）的抑制物與其應用方法
WO2008070609A1 (en) * 2006-12-04 2008-06-12 Janssen Pharmaceutica N.V. Thienyl-containing glycopyranosyl derivatives as antidiabetics
UY30730A1 (es) * 2006-12-04 2008-07-03 Mitsubishi Tanabe Pharma Corp Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno
WO2008109591A1 (en) * 2007-03-08 2008-09-12 Lexicon Pharmaceuticals, Inc. Phlorizin analogs as inhibitors of sodium glucose co-transporter 2
NZ600110A (en) 2007-09-10 2013-03-28 Janssen Pharmaceutica Nv Process for the preparation of compounds useful as inhibitors of sglt
CL2008003653A1 (es) 2008-01-17 2010-03-05 Mitsubishi Tanabe Pharma Corp Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
JP5820269B2 (ja) 2008-05-22 2015-11-24 アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ Ｓｇｌｔ２阻害剤を使用する高尿酸血症の治療方法およびｓｇｌｔ２阻害剤を含有する組成物
AP2728A (en) 2008-08-28 2013-08-31 Pfizer Dioxa-bicyclo[3.2.1.] octane-2,3,4-triol derivatives
WO2010031813A1 (en) * 2008-09-19 2010-03-25 Novartis Ag Glycoside derivatives and uses thereof
US9056850B2 (en) * 2008-10-17 2015-06-16 Janssen Pharmaceutica N.V. Process for the preparation of compounds useful as inhibitors of SGLT
US20110009347A1 (en) 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
US8772512B2 (en) 2009-07-10 2014-07-08 Janssen Pharmaceutica Nv Crystallisation process for 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl] benzene
PH12012500698A1 (en) * 2009-10-14 2016-05-27 Janssen Pharmaceutica Nv Process for the preparation of compounds useful as inhibitors of sglt2
DK2496583T3 (en) 2009-11-02 2015-02-02 Pfizer Dioxa-bicyclo [3.2.1] octane-2,3,4-triol DERIVATIVES
ES2596291T3 (es) 2010-05-11 2017-01-05 Janssen Pharmaceutica, N.V. Formulaciones farmacéuticas que comprenden derivados de 1-(beta-d-glucopiranosil)-2-tienilmetilbenceno como inhibidores de sglt
CN103596944B (zh) 2011-04-13 2017-02-22 詹森药业有限公司 可用作sglt2的抑制剂的化合物的制备方法
US9035044B2 (en) * 2011-05-09 2015-05-19 Janssen Pharmaceutica Nv L-proline and citric acid co-crystals of (2S, 3R, 4R, 5S,6R)-2-(3-((5-(4-fluorophenyl)thiopen-2-yl)methyl)4-methylphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol
WO2014132940A1 (ja) * 2013-02-26 2014-09-04 田辺三菱製薬株式会社 α－ハロテトラアシルグルコースの製造方法
CN103896930B (zh) * 2014-04-02 2016-08-17 安徽联创生物医药股份有限公司 卡格列净半水合物药用晶型的制备方法
EP3148979B1 (en) 2014-05-27 2019-02-06 Glenmark Pharmaceuticals Limited Process for preparation of canagliflozin
CN104045673B (zh) * 2014-06-06 2017-01-18 安徽省食品药品检验研究院 双‑三氮唑缀合的假二糖衍生物及其制备方法
CN104478968A (zh) * 2015-01-14 2015-04-01 佛山市赛维斯医药科技有限公司 含噻唑基的o-半乳糖苷衍生物、其制备方法和用途
CN106188022A (zh) * 2015-04-30 2016-12-07 上海医药工业研究院 伊格列净的制备方法
US20170071970A1 (en) 2015-09-15 2017-03-16 Janssen Pharmaceutica Nv Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
US12144811B2 (en) 2017-11-30 2024-11-19 Idorsia Pharmaceuticals Ltd Combination of a 4-pyrimidinesulfamide derivative with an SGLT-2 inhibitor for the treatment of endothelin related diseases
WO2020016335A1 (en) 2018-07-19 2020-01-23 Astrazeneca Ab Methods of treating hfpef employing dapagliflozin and compositions comprising the same
SI4188389T1 (sl) 2020-07-27 2025-11-28 Astrazeneca Ab Dapagliflozin za uporabo pri postopkih zdravljenja kronične ledvične bolezni
TW202220672A (zh) 2020-07-27 2022-06-01 瑞典商阿斯特捷利康公司 用達格列淨治療慢性腎臟病之方法
US20240212818A1 (en) 2021-04-01 2024-06-27 Astrazeneca Uk Limited Systems and methods for managing prediabetes with a gliflozin sodiumglucose cotransport 2 inhibitor pharmaceutical composition
US20250108065A1 (en) 2022-01-26 2025-04-03 Astrazeneca Ab Methods of treating prediabetes or reducing the risk of developing type 2 diabetes with dapagliflozin
WO2025125513A1 (en) 2023-12-15 2025-06-19 AstraZeneca Ireland Limited Sglt2 inhibitors and baxdrostat for treating chronic kidney disease and hypertension

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1075626B (de) * 1960-02-18 Farbwerke Hoechst Aktiengesellschaft vormals Meister Lucius &. Brunmg, Frankfurt/M Verfahren zur Herstellung von wasserlöslichen chemotherapeutisch wirksamen Glykosiden
PH12000002657B1 (en) 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
CZ20023023A3 (cs) * 2000-03-17 2003-04-16 Kissei Pharmaceutical Co., Ltd. Glukopyranosyloxybenzylbenzenové deriváty, léčivé směsi obsahující tyto látky a meziprodukty pro přípravu derivátů
US6683056B2 (en) * 2000-03-30 2004-01-27 Bristol-Myers Squibb Company O-aryl glucoside SGLT2 inhibitors and method
EP1329456B1 (en) * 2000-09-29 2006-08-09 Kissei Pharmaceutical Co., Ltd. Glucopyranosyloxybenzylbenzene derivatives and medicinal compositions containing the same
CA2429833A1 (en) * 2000-11-30 2002-06-06 Kissei Pharmaceutical Co., Ltd. Glucopyranosyloxybenzylbenzene derivatives, medicinal compositions containing the same and intermediates in the production thereof
MXPA03005923A (es) 2000-12-28 2004-01-26 Kissei Pharmaceuticals Co Ltd Derivados de glupopiranosiloxipirazol y su uso en medicinas.
TWI255817B (en) * 2001-02-14 2006-06-01 Kissei Pharmaceutical Glucopyranosyloxybenzylbenzene derivatives and medicinal use thereof
US20030087843A1 (en) * 2001-09-05 2003-05-08 Washburn William N. O-pyrazole glucoside SGLT2 inhibitors and method of use
DE102004048388A1 (de) * 2004-10-01 2006-04-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg D-Pyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung

Also Published As

Publication number Publication date
US20070060545A1 (en) 2007-03-15
UA86599C2 (en) 2009-05-12
TWI377209B (en) 2012-11-21
IL173051A0 (en) 2006-06-11
ZA200601686B (en) 2007-05-30
NO333679B1 (no) 2013-08-05
KR101101500B1 (ko) 2012-01-03
MXPA06001273A (es) 2006-04-11
US7521430B2 (en) 2009-04-21
IL173051A (en) 2012-06-28
EP1654269A1 (en) 2006-05-10
BRPI0413233A (pt) 2006-10-03
AU2004260760A1 (en) 2005-02-10
CA2534022A1 (en) 2005-02-10
TW200510440A (en) 2005-03-16
KR20060132539A (ko) 2006-12-21
NO20060219L (no) 2006-04-28
EP1654269B1 (en) 2014-10-15
CA2534022C (en) 2012-10-02
ZA200603880B (en) 2010-01-27
CN1829728A (zh) 2006-09-06
UA83377C2 (ru) 2008-07-10
EA200600348A1 (ru) 2006-08-25
UA86042C2 (en) 2009-03-25
WO2005012321A1 (en) 2005-02-10
AU2004260760B2 (en) 2009-08-13
ES2527053T3 (es) 2015-01-20
JP4717811B2 (ja) 2011-07-06
UA87991C2 (en) 2009-09-10
JP2007518682A (ja) 2007-07-12
NZ545305A (en) 2008-11-28
EA011025B1 (ru) 2008-12-30
CN102060888A (zh) 2011-05-18

Similar Documents

Publication Publication Date Title
UA85569C2 (ru) Замещенные конденсированные гетероциклические с-гликозиды
WO2005012318A3 (en) Substituted fused heterocyclic c-glycosides
WO2005012242A3 (en) Substituted benzimidazole-, benztriazole-, and benzimidazolone-o-glucosides
MY142777A (en) Substituted indole-o-glucosides
EA200601555A1 (ru) Замещенные индазол-о-глюкозиды
TW200604184A (en) Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
TN2009000111A1 (en) Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
TW200738724A (en) Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
MX2007003108A (es) Compuestos imidazo-3-il-amina sustituidos y biciclicos.
NO20044221L (no) Nye forbindelser
UA86591C2 (ru) Пирролодигидроизохинолины как ингибиторы pde10, фармацевтическая композиция на их основе
UA101478C2 (ru) Соединения, полезные как ингибиторы raf-киназы
PL1682530T3 (pl) Podstawione pirolo-indole jako inhibitory PAI-1
MX2007005221A (es) Formas cristalinas de ascomicina y preparacion de ellas.
MXPA05009885A (es) Nuevas triazolonas fusionadas y los usos de las mismas.
PL1620425T3 (pl) Podstawione 3-cyjanotiofenoacetamidy jako antagoniści receptora glukagonu
MXPA05004621A (es) Derivados de anilinopirazol utiles en el tratamiento de la diabetes.
DK1456212T3 (da) 6-aminomorphinanderivater, fremgangsmåder til fremstilling heraf og disses anvendelse
MXPA05009151A (es) Inhibidores de cinasa heterociclica.
MXPA04007391A (es) Heterociclos triciclicos fusionados utiles para el tratamiento de padecimientos hiper-proliferantes.
MXPA06000986A (es) Compuestos.
ATE419242T1 (de) Pyrrolidinylharnstoffderivate als angiogeneseinhibitoren
TW200616977A (en) Enantiomers of selected fused heterocyclics and uses thereof
UA74430C2 (ru) Производные фенилгетероциклических этеров как ингибиторы обратного захвата серотонина
DE60316128D1 (de) N-sulfonylurea-apoptosis-förderer